Trial Profile

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Datopotamab deruxtecan (Primary) ; Capecitabine; Carboplatin; Eribulin; Paclitaxel; Paclitaxel
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms TROPION Breast02
Sponsors AstraZeneca

04 Jul 2024 Status changed from recruiting to active, no longer recruiting.
10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.
21 Nov 2022 According to a Daiichi Sankyo Company media release, data from the trial will be presented at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com